北大醫藥(000788.SZ)：2019年淨利同比增11.09% 擬不進行利潤分配
格隆匯5月28日丨北大醫藥(000788.SZ)披露2019年年度報告，2019年，公司實現營業收入25.09億元，較去年同期增長8.35%；歸屬於母公司所有者的淨利潤5018.86萬元，較去年同期增長11.09%。公司主營業務的醫藥工業實現了快速增長，營業收入達8.99億元、利潤總額達3,443.32萬元、淨利潤達2,744.18萬元，分別較上年同期增長24.85%、14.09%和20.74%。公司醫藥工業營業收入增速高於國內醫藥製造業17.45個百分點，利潤總額增速高於國內醫藥製造業8.19個百分點(國家統計局數據顯示,2019年度,醫藥製造業營業收入比上年增長7.4%；利潤總額比上年增長5.9%)。公司經營業績保持了穩健增長。報告期內，公司研發投入較去年同比增長70.15%，主要系公司一致性評價研發及新產品的引進投入。
2019年度權益分派預案經2020年5月28日召開的第九屆董事會第十三次會議及第九屆監事會第十一次會議審議通過，公司擬定2019年度公司利潤分配預案為不進行利潤分配，亦不進行資本公積金轉增股本。
公司所屬行業為醫藥製造業。本報告期內公司主要從事化學藥品製劑的研發、生產和銷售，醫藥流通以及醫療服務等業務。
簡要情況如下：
1、藥品研發：擁有國家級技術中心，依託北京大學醫學部深厚的學術基礎以及北大醫療旗下研發企業的研發資源，進行自主研發與合作研發。在研產品涵蓋精神類、抗感染類、消化系統類、抗腫瘤類等多個領域。
2、製劑業務：目前製劑銷售以國內市場為主，上市的製劑產品主要覆蓋抗感染類、內分泌類、精神類、消化系統類、心血管類、鎮痛等；此外，公司擁有健全的營銷網絡和覆蓋全國的營銷渠道，並能夠合法、有效開展藥品銷售活動。
3、流通業務：通過北醫醫藥、武漢葉開泰兩家全資子公司從事第三方藥品、器械和耗材的分銷、零售、醫院集採、藥房託管等業務。
4、醫療服務：主要是公司參股的腫瘤醫院管理公司控股的迦南門診從事的腫瘤篩查、健康管理及診療等服務。報告期內，公司立足於現有的產品、業務、資源和能力，堅持“重醫藥工業，優化醫藥商業”，通過外延性拓展持續夯實醫藥製劑業務，在優勢品種領域繼續深耕、拓展，營銷渠道繼續擴面下沉，實現終端多點開花。同時，在經營理念上公司堅持利潤為導向，堅持效率與效益優先，用機制激活效率與效益實現了公司業績的穩定增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
